FdaApplication
NDA 215256
Identifiers
- fda_app_no: NDA215256
Properties
| Property | Value |
|---|---|
| applicant_name | NOVO NORDISK INC |
| application_type | NDA |
| approval_date | 2021-06-04 |
Products (12)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| WEGOVY | SEMAGLUTIDE | 2.4MG/0.75ML (2.4MG/0.75ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 2.4MG/0.75ML (2.4MG/0.75ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 0.25MG/0.5ML (0.25MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 0.5MG/0.5ML (0.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 1.7MG/0.75ML (1.7MG/0.75ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 0.25MG/0.5ML (0.25MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 1MG/0.5ML (1MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 1MG/0.5ML (1MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 0.5MG/0.5ML (0.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY | SEMAGLUTIDE | 1.7MG/0.75ML (1.7MG/0.75ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY FLEXTOUCH | SEMAGLUTIDE | 9.6MG/3ML (3.2MG/ML) | SOLUTION;SUBCUTANEOUS |
| WEGOVY HD | SEMAGLUTIDE | 7.2MG/0.75ML (7.2MG/0.75ML) | SOLUTION;SUBCUTANEOUS |
12 products